- Home
- BEEP vs KZIA Comparison
BEEP vs KZIA Comparison
Compare BEEP & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEEP | KZIA |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.5M | 100.8M |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BEEP | KZIA |
|---|---|---|
| Price | $2.07 | $11.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.50 | ★ $19.50 |
| AVG Volume (30 Days) | 23.6K | ★ 180.4K |
| Earning Date | 05-12-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,075,000.00 | N/A |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $22.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.00 | $2.90 |
| 52 Week High | $4.67 | $17.40 |
Technical Indicators
Market Signals| Indicator | BEEP | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 74.94 |
| Support Level | $2.00 | $5.73 |
| Resistance Level | $3.24 | $14.42 |
| Average True Range (ATR) | 0.18 | 1.08 |
| MACD | 0.01 | 0.32 |
| Stochastic Oscillator | 16.28 | 89.58 |
Price Performance
Historical ComparisonAbout BEEP Mobile Infrastructure Corporation
Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.